Notably, the main population of TAMs in skin cancer is CD163+ M2 macrophages [1], with sCD163 as the activation marker [94], suggesting that CD163 activated with PD1 antibody should release sCD163 in the tumor microenvironment. This evidence concerns the gene CD163 and skin cancer.